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Abstract
Background
Whether patients waitlisted for a second transplant after failure of a previous kidney graft
have higher mortality than transplant-na¨ive waitlisted patients is uncertain.
Methods
We assessed the relationship between a failed transplant and mortality in 3851 adult KT
candidates, listed between 1984–2012, using a competing risk analysis in the total popula-
tion and in a propensity score-matched cohort. Mortality was also modeled by inverse prob-
ability weighting (IPTW) competing risk regression.
Results
At waitlist entry 225 (5.8%) patients had experienced transplant failure. All-cause mortality
was higher in the post-graft failure group (16% vs. 11%; P = 0.033). Most deaths occurred
within three years after listing. Cardiovascular disease was the leading cause of death
(25.3%), followed by infections (19.3%). Multivariate competing risk regression showed that
prior transplant failure was associated with a 1.5-fold increased risk of mortality (95% confi-
dence interval [CI], 1.01–2.2). After propensity score matching (1:5), the competing risk
regression model revealed a subhazard ratio (SHR) of 1.6 (95% CI, 1.01–2.5). A similar
mortality risk was observed after the IPTW analysis (SHR, 1.7; 95% CI, 1.1–2.6).
Conclusions
Previous transplant failure is associated with increased mortality among KT candidates after
relisting. This information is important in daily clinical practice when assessing relisted
patients for a retransplant.
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Introduction
Loss of a kidney graft has emerged as an important cause of end-stage renal disease (ESRD).
Most affected patients need to return to dialysis, with some relisted for transplantation [1,2].
Patients on the waiting list for kidney transplantation (KT) have a lower mortality risk
than those not listed [3]. However, patients relisted after graft failure have a decreased sur-
vival compared with transplant-naïve (TN) patients waitlisted for KT [4–7]. Transplanta-
tion is not usually considered a classical risk factor for death, but KT is generally associated
with a high burden of immunosuppression and comorbid conditions, which could lead to
life-threatening complications and thus increase mortality when these patients are relisted.
Additionally, whether the effect of a prior KT on survival of relisted patients changes over
the time these patients are on the waiting list is undetermined. The question, therefore, is
whether patients who are waitlisted following a failed KT are at increased risk for death rela-
tive to TN patients waitlisted for KT. Accordingly, a more appropriate comparison group
for patients waitlisted after graft failure would be patients deemed eligible to receive a pri-
mary transplant.
Observational studies have assessed survival of patients returning to dialysis after graft
failure, but most studies involved heterogeneous patient groups (e.g. waitlisted and not
waitlisted) or were single-center studies with relatively small sample sizes and of limited
generalizability [4–13]. Consequently, explicit comparisons of mortality between patients
waitlisted after graft failure and TN patients waitlisted for KT are lacking [5], especially
studies that use proper assessment of survival in this particular population, such as a com-
peting risk analysis, where transplantation may be considered a competing risk when eval-
uating survival in waitlisted patients [14,15]. In addition, as transplant clinicians do not
randomly allocate waitlisted patients for KT a propensity score analysis should be per-
formed when assessing survival to avoid potential selection bias between waitlisted patients
who have received a prior transplant and TN waitlisted patients [16]. Importantly however,
no large-scale study has yet used a competing risk approach and propensity score analyses
to address the question of whether patients who are relisted following a failed transplant
are at increased risk for death relative to waitlisted patients who have not yet received a
transplant. In light of this, therefore, we undertook competing risk analyses and a propen-
sity score analysis to compare survival of patients waitlisted for KT after graft failure with
that of TN waitlisted patients. We hypothesized that relisted patients have an increased risk
of mortality.
Material and methods
Study population
This longitudinal cohort study involved 22,497 renal patients included in the Andalusian Reg-
istry of Renal Patients between January 1, 1984, and July 31, 2012, because of initiation of dial-
ysis. Data from all centers in Andalusia, a region in southern Spain with nearly 9 million
inhabitants, were entered into the registry with follow-up information through July 31, 2012.
The database is updated annually and the degree of compliance of data concerning waitlist
patients was almost universal. Details of the study design have been reported, as have the base-
line clinical and demographic data of the study population [14]. Briefly, we excluded 18,560
patients not listed for KT at entry to dialysis, including pre-emptive KT, and 86 patients youn-
ger than 18 years. We therefore assessed a final total population of 3851 adult KT candidates
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(225 relisted after a failed graft and 3626 TN). Of these, 1975 received a KT (72 a retransplant
and 1903 TN) and 1876 were on the waitlist at any time during the study period (153 relisted
and 1723 TN) (Fig 1). Of the 72 retransplanted patients, 5 died, 2 experienced graft loss due to
chronic allograft nephropathy and one was lost to follow-up. The overall total median time on
the waiting list was 21.2 months (interquartile range, 11–37.4). The clinical characteristics of
the waitlisted patients and the KT recipients are shown in supplementary material (S1 Table).
A higher age and a greater proportion of comorbidities were observed in the waiting-list group
compared with the patients who received a KT [14]. Inactive status was defined as candidates
not suitable for transplantation, for whatever reason, at the time of waitlist inclusion or while
on the waiting list (incomplete workup, medical noncompliance, inappropriate weight, tempo-
rarily too sick, etc.), but still an appropriate patient to remain on the waiting list. Consequently,
we also took into account “inactive status” within the waitlist (n = 316) when performing sur-
vival analyses because these patients had not been definitively removed from the waitlist. We
therefore evaluated survival of all patients who remained on the waitlist during follow-up,
including inactive status patients.
Some recommendations for keeping a patient on the waiting list or removing someone
from it are broad rather than specific and are based on clinical practice guidelines on waitlist-
ing for KT [17,18].
Fig 1. Flow chart of the study population. ESRD, end-stage renal disease; KT, kidney transplant; TN transplant-na¨ive.
https://doi.org/10.1371/journal.pone.0193091.g001
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The following data were recorded at the start of dialysis: (a) demographic and clinical data:
age, sex, cause of ESRD and comorbidities compiled in the Charlson comorbidity index (CCI)
[19]: myocardial infarction and congestive heart failure (grouped as cardiac disease), peripheral
vascular disease, hemiplegia, diabetes, connective tissue disease, mild liver disease (considered
as the presence of hepatitis B surface antigen or positive hepatitis C virus antibodies without cir-
rhosis), cirrhosis, chronic pulmonary disease, peptic ulcer, any tumor without metastasis, and
HIV infection; (b) conditions and comorbidities inherent to the uremia: dialysis modality at
entry (hemodialysis versus peritoneal dialysis), presence of a central venous catheter (CVC) at
dialysis entry regardless of dialysis modality, time on waitlist (defined as time from waitlist
inclusion until end of follow-up or permanent or temporary withdrawal from the waiting list),
total time on dialysis (defined as time from starting dialysis until end of follow-up, including
time on waitlist for a first KT and time on dialysis whist awaiting a second, third or fourth trans-
plant–that is, the sum of all periods on dialysis throughout the follow-up), and previous trans-
plant, considering also as a covariate one or more previous transplants; and (c) community risk
factors, e.g. early or late referral to the nephrologist (considered as a cut-off time of 6 months)
and employment status (employed vs. unemployed or retired because of age or disability).
Lastly, the waitlisted year was also registered, grouped in 4- or 5-year periods (1984–1987 vs.
1988–1992 vs. 1993–1997 vs. 1998–2002 vs. 2003–2007 vs. 2008–2012).
Medical record review was approved by the ethics committee of Carlos Haya Regional Uni-
versity Hospital and conducted according to the Declaration of Helsinki. As the patient data in
the third-party database were de-identified prior to access by the authors, the ethics committee
waived patient approval. The datasets can be accessed in the same manner as the authors via a
request to the Transplant Coordinator of the Andalusian Health Service (Seville, Spain). The
authors themselves had no special access privileges.
Outcome
Mortality whilst on the waitlist was the clinical endpoint. Survival was measured in months
from waitlist inclusion, with patients censored at the time of permanent or temporary waitlist
withdrawal for any reason, including KT, inactive status or last follow-up (31 December,
2012). We took into account competing events. Thus, survival analyses were performed using
a competing risk approach, where KT and inactive status condition were treated as competing
events. Survival data were available for the whole population and all deaths while on the wait-
ing list were recorded. Survival analysis considered the whole study population; that is, all
active and inactive status patients on the waitlist. Survival was also analyzed excluding inactive
status and diabetic patients.
Statistical analysis
Continuous data were expressed as mean±standard deviation or median and interquartile
range. Comparisons of continuous variables between patients waitlisted after graft failure and
TN patients waitlisted for KT were performed using unpaired t-test. Absolute and relative fre-
quencies were used to describe categorical variables, which were compared between both
groups using the chi-square test.
As a result of an imbalance in clinical characteristics between patients waitlisted after a
prior transplant and TN patients waitlisted for KT, a propensity score-matched pair analysis
was used to compare outcomes between the two patient groups with similar predicted proba-
bilities of receiving a previous KT. We therefore created a multivariable logistic regression
model to estimate the propensity score for receiving a previous transplant by using a greedy
matched pair analysis that has a 1:5 matching algorithm with replacement [20,21]. Covariates
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used for this analysis were the clinical characteristics of the patients, including comorbidities,
diabetes condition, time on dialysis, listing year grouped in 4- or 5-year periods (1984–1987
vs. 1988–1992 vs. 1993–1997 vs. 1998–2002 vs. 2003–2007 vs. 2008–2012), a CVC, late nephr-
ologist referral, employment status and dialysis modality. To assess the effectiveness of bias
reduction after the matching procedure we measured absolute standardized differences,
expressed as a percentage of the pooled standard deviation, and compared differences between
matched groups [22]. We evaluated iteratively various caliper widths until between-group
standardized differences were minimized. The final selected caliper width was 0.05 and TN
waitlisted patients were sampled with replacement. As a sensitivity analysis we also explored a
different method, inverse probability weighting (IPTW), to assess the issue of confounding for
indication [23].
We used a competing risk approach where KT and inactive status condition were managed
as competing events that compete with our clinical end-point. In particular, competing risk
regression models were applied directly to the cumulative incidence function for particular use
in competing risks analyses, as described by Fine and Gray [24]. Three strategies were used to
assess the association between prior KT and mortality in waitlisted patients by using compet-
ing risk regression models. Firstly, we used a multivariate adjustment competing risk model in
the total study population. Adjustment covariates included comorbidities compiled in the
CCI, including diabetes condition, age, sex, presence of a CVC regardless of dialysis modality,
late referral to nephrologist, employment status, dialysis modality, time on dialysis, previous
transplant (yes/no), number of previous transplants and listing time periods (1984–87 vs.
1988–92 vs. 1993–97 vs. 1998–2002 vs. 2003–07 vs. 2008–12). Second, a competing risk regres-
sion model was fitted to the propensity score-matched cohort. The adjusted model on the
matched set included covariates that had standardized differences of>10% [25]. Finally, the
primary endpoint was modeled by a IPTW competing risk regression model. These models
were fitted using the stcrreg Stata command.
Time on waitlist for both TN waitlisted patients and patients waitlisted after graft failure
was defined in our survival analyses as the time from placement on the waiting list (time zero)
until permanent or temporary withdrawal for any reason (death, KT or inactive status) or last
follow-up (31 December, 2012). The start of the time on the waitlist (time zero) for the post-
graft failure dialysis group was defined as the date they were included on the waiting list after
returning to long-term dialysis.
We used psmatch2 for the propensity score analyses and SPSS version 15.0 (SPSS, Inc., Chi-
cago, IL) and Stata version 13.1 (StataCorp LP., College Station, TX) for all other analyses. A P
value <0.05 was considered significant.
Missing values
Although the data on mortality were complete, some clinical data were not available for all the
3851 patients included in the study. Nevertheless, there were relatively few missing values,
including in the subset of patients relisted after graft failure (<10%). Missing data were treated
by means of multiple imputation [26]. Because a large subset of the population (93%) had no
missing data, final survival analysis was not affected by missing data.
Results
Of the 3851 patients included in the study, 225 (5.8%) had had a prior transplant at the start of
dialysis. Of these 225, 204 had received just one previous transplant, 20 had received two previ-
ous transplants and only one had received three transplants. Table 1 summarizes the baseline
clinical and demographic characteristics for the patients waitlisted after allograft failure and
Waitlist survival after kidney graft failure: Competing risk analysis
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the TN waitlisted patients. Significant differences were observed between the groups for age,
sex, primary cause of ESRD, type of dialysis at entry, late referral to nephrologist and comor-
bidities, including peripheral vascular disease, mild liver disease and chronic pulmonary dis-
ease. In addition, a higher proportion of TN waitlisted patients received a KT (52%), whereas
only 32% of patients waitlisted after graft failure received a KT. Accordingly, these patients
who had already experienced graft failure had a higher median time on dialysis.
Table 1. Clinical and demographic characteristics of patients waitlisted after allograft failure versus transplant-naïve waitlisted patients.
Patients waitlisted after graft failure (n = 225) Transplant-naïve waitlisted patients (n = 3626) P value
Mean age, y 48.4±14 53.3±13.5 <0.001
Male, % 56 63 0.027
Cardiac disease, % 5.3 7.8 0.180
Heart failure 4.4 6.5
Myocardial infarction 0.9 1.7
Hemiplegia 0.9 2.2 0.328
Chronic pulmonary disease, % 2.2 5.3 0.041
Connective tissue disorder, % 4 4.2 0.905
Primary cause of renal disease %
Diabetes 8 17.4 <0.001
Gomerulonephritis 21 12
Polycystic disease 11.6 12
Nephrosclerosis 4.4 10
Interstitial nephritis 15 11
Unknown 21 28
Other 18 10
Mild liver disease^, % 8 3 <0.001
Cirrhosis, % 0.9 1.2 1.000
HIV positive, % 0.4 0.8 1.000
Peptic ulcer, % 2.7 2.8 1.000
Any tumor without metastasis, % 2.2 3.1 0.687
Hemodialysis at entry, % 73 81 0.005
Central venous catheter, % 29 35 0.071
Peripheral vascular disease, % 4.4 8.2 0.042
Late referral, % 18.7 25.2 0.026
Unemployed status^^, % 56 58 0.677
Median CCI (IR) 3 (2–4) 4 (2–5) <0.001
Median total time on dialysis+ (IR), mo 24 (11–55) 21 (11–38) 0.037
KT recipients, % 32 52 <0.001
Cardiac disease was considered as heart failure or myocardial infarction.
^Mild liver disease was considered as the presence of hepatitis B surface antigen or positive hepatitis C virus antibodies without cirrhosis.
 A 6-month cut-off time was defined for late referral to nephrologist
^^Unemployed status was considered as unemployed or retired because of age or disability
+Total time on dialysis was defined as time from starting dialysis until end of follow-up, including time on waitlist for a first KT and time on dialysis whilst awaiting a
second, third or fourth transplant. Thus, total time on dialysis represents the sum of all periods on dialysis throughout the follow-up.
Abbreviations: PVD, peripheral vascular disease; HIV, human immunodeficiency virus; CCI, Charlson comorbidity index; KT, kidney transplantation; IR, interquartile
range.
https://doi.org/10.1371/journal.pone.0193091.t001
Waitlist survival after kidney graft failure: Competing risk analysis
PLOS ONE | https://doi.org/10.1371/journal.pone.0193091 March 7, 2018 6 / 15
After 1:5 propensity score matching, differences across the two groups diminished substan-
tially (Table 2), reflected by a reduction in the absolute standardized difference across almost
all the clinical data analyzed when assessing matched cohorts.
Table 2. Clinical characteristic of patients waitlisted after graft failure versus transplant-na¨ive waitlisted patients after matching 1:5 with replacement.
Patients waitlisted after graft failure (n = 225) Transplant-naïve waitlisted patients (n = 667) Absolute standardized difference
Mean age, y 48.4±14 46.7±14 11.6
Cardiac disease, % 5.3 6.1 2.9
Hemiplegia, % 0.9 1.1 2.2
Chronic pulmonary disease, % 2.2 2.1 0.5
Connective tissue disorder, % 4 4.5 2.7
Diabetes, % 8 8.3 1.1
Mild liver disease^, % 8 5.6 10.5
Cirrhosis, % 0.9 0.5 3.5
HIV positive, % 0.4 0.7 3.4
Peptic ulcer, % 2.7 1.3 8.1
Any tumor without metastasis, % 2.2 2 1.1
Hemodialysis at entry, % 73 73.5 1.5
Central venous catheter, % 29 25 7.8
Peripheral vascular disease, % 4.4 4 1.8
Late referral , % 18.7 20.8 5.2
Unemployed status^^, % 56 55 2.9
Listing period, %
1988–1992 11.1 10.3 3.5
1993–1997 12.4 12 2.2
1998–2002 10.6 12.4 7.4
2003–2007 41.3 40.8 1.1
2008–2012 16.4 16.3 0.2
Cardiac disease was considered as heart failure or myocardial infarction.
^Mild liver disease was considered as the presence of hepatitis B surface antigen or positive hepatitis C virus antibodies without cirrhosis.
 A 6-month cut-off time was defined for late referral to nephrologist
^^Unemployed status was considered as unemployed or retired because of age or disability
Abbreviations: HIV, human immunodeficiency virus.
https://doi.org/10.1371/journal.pone.0193091.t002
Table 3. Causes of death among patients who remained on the waiting lista (n = 1876 patients and 446 deaths)
after allograft failure versus transplant-naïve waitlisted patients.
Cause of death Patients waitlisted after graft failure (n = 36) Transplant-naïve waitlisted patients (n = 410)
Cardiovascularb 11 (30.6) 101 (24.6)
Infection 8 (22.2) 78 (19)
Neoplasm 2 (5.6) 30 (7.3)
Liver disorder 1 (2.8) 9 (2.2)
Uncertain 10 (27.8) 119 (29)
Miscellaneous 4 (11) 73 (17.8)
aExpressed as number (%)
bCauses of death from cardiovascular disease included myocardial infarction, heart failure, stroke, arrhythmia,
peripheral vascular event, and sudden death
https://doi.org/10.1371/journal.pone.0193091.t003
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Survival
The overall median follow-up was 22 months (interquartile range 11–39 months). A total of
446 (24%) patients died while they remained on the waiting list (n = 1876) (Table 3). Overall,
cardiovascular diseases were the leading cause of mortality (25.3%), followed by infectious
complications (19.3%), cancer (7.2%) and hepatic disorders (3%). Miscellaneous causes,
including those from an unknown source, accounted for 46%. Of note, patients waitlisted after
graft failure experienced a higher all-cause mortality than waitlisted TN patients (16% vs. 11%;
P = 0.033). Likewise, a trend toward higher cardiovascular mortality was seen in patients wait-
listed after graft failure compared with waitlisted TN patients (Table 3) despite the former
being younger and having a lower burden of comorbidities at dialysis entry (Table 1). Most
deaths of waitlisted patients occurred within the first three years after listing and a significantly
higher mortality occurred among those patients waitlisted after graft failure versus waitlisted
TN patients (chi-square 42.8; P<0.0001), especially at the third year post-listing (Fig 2). Fig 3
shows the cumulative incidence of deaths while on the waiting list over time in both groups
according to the propensity score-matched analysis. Finally, among the patients waitlisted
after graft failure who died (n = 36), 33 had received only one previous transplant, while three
had received two transplants.
Table 4 shows the results of the competing risk regression model. After adjustment for age,
comorbidities included in the CCI, uremia-related factors, several community risk factors, and
listing periods, the subhazard ratio (SHR) estimate for mortality in patients waitlisted after
graft failure was 1.5 (95% confidence interval [CI], 1.01–2.2). Other risk factors for mortality
Fig 2. Proportion of deaths in both groups of waiting-list patients according to time on list. Overall comparison: chi-
square = 42.8; P<0.0001 P = 0.029 vs. transplant-na¨ive waitlisted patients (chi-square = 4.77).
https://doi.org/10.1371/journal.pone.0193091.g002
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in the multivariate model were age (SHR 1.04; 95% CI, 1.03–1.05), cardiac disease (SHR 1.7;
95% CI, 1.5–2.2), diabetes (SHR 2.2; 95% CI, 1.7–2.7), connective tissue disorder (SHR 1.7;
95% CI, 1.2–2.6), peripheral vascular disease (SHR 1.8; 95% CI, 1.4–2.3), liver disease (SHR
Fig 3. Estimated survival curves for death while on the waiting list in both groups adjusted for confounders using competing risk
analysis.
https://doi.org/10.1371/journal.pone.0193091.g003
Table 4. Multivariate competing risk analysis for the relationship between post-graft failure and mortality in
relisted patients for kidney transplantationa.
Statistical models Competing risk SHRb (95% CI) P value
Adjustedc 1.5 (1.01–2.2) 0.045
Propensity score-matched cohortd 1.6 (1.01–2.5) 0.042
IPTWe (weighted estimates) 1.7 (1.1–2.6) 0.018
aTransplant-na¨ive waitlisted patients is the reference group.
bSubhazard ratios are from competing risk models (n = 3851 and 1975 kidney transplant patients and 279 inactive
status).
cAdjustments in multivariate models were made for age, sex, cardiac disease, hemiplegia, chronic pulmonary disease,
connective tissue disorder, diabetes, mild liver disease, cirrhosis, HIV positive, peptic ulcer, any tumor without
metastasis, hemodialysis at entry, central venous catheter, peripheral vascular disease, late referral, unemployed
status, time on dialysis and listing periods (1984–1987 vs. 1988–1992 vs. 1993–1997 vs. 1998–2002 vs. 2003–2007 vs.
2008–2012).
dAdjusted for age and mild liver disease
eInverse probability weighting estimates
https://doi.org/10.1371/journal.pone.0193091.t004
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2.3; 95% CI, 1.5–3.3), the presence of a central venous catheter (SHR 1.8; 95% CI, 1.5–2.2),
unemployed status (SHR 1.7; 95% CI, 1.4–2.1 and any tumor without metastasis (SHR 1.7;
95% CI, 1.1–2.6). Estimated survival curves for death while on the waiting list in both groups
adjusted for confounders using competing risk analysis are plotted in Fig 3. When a subanaly-
sis was performed excluding those patients who were relisted between 1984–1988 and were
under azathioprine-based immunosuppression, the adjusted competing risk regression model
revealed a subhazard ratio estimate for mortality of 1.42 (95% CI, 0.94–2.1; P = 0.09). The SHR
estimate from the propensity score-matched cohort for death was 1.6 (95% CI, 1.01–2.5).
Finally, a similar SHR estimate for mortality was observed when the primary endpoint (death)
was modeled by IPTW competing risk model (SHR, 1.7; 95% CI, 1.1–2.6) (Table 4).
Discussion
This large cohort study of waitlisted candidates for KT demonstrates for the first time that
patients waitlisted after a graft failure have an increased risk of mortality after listing compared
with TN patients waitlisted for KT by using a competing risk approach and propensity score
analyses. All the patients in our analysis were at some point on the KT waiting list, which
makes the groups suitable for comparison. Accordingly, our findings will aid clinical decision
making when considering relisted patients for another transplant.
The prevalence of patients waitlisted after graft failure (5.8%) was lower than that reported
for this particular population, especially in other European and North American registries
[2,4,5]. This lower prevalence rate could be due to the ample study period assessed in our
cohort study (1987–2012), noting different clinical management in patients after graft failure
over this long time. Whether high variability in practice patterns in country-specific dialysis
and transplant recipient populations, as has been previously suggested [4,27], could justify
these differences remains undetermined.
Although patients who return to dialysis after a failed graft have a higher risk of death
while on the waiting list, the relationship between prior KT and mortality after relisting has
not been explicitly assessed. Indeed, the comparison group in most previous reports was
either KT recipients with a functioning graft or all patients undergoing dialysis, not just
those on the waiting list, which could have attenuated the post-graft failure effect on mortal-
ity [4–6,8–11,13,28]. One large cohort study has assessed survival in patients waitlisted after
graft failure, comparing them with primary KT candidates in a sensitivity analysis [5]. In
that study, when the post-graft failure dialysis group was restricted to relisted patients, the
mortality rate still remained significantly increased (32%) using conventional survival anal-
yses. Similarly, another large study using conventional Cox regression methods found a
higher risk of death in patients who return to dialysis after transplant failure [7]. However,
neither of these studies undertook a competing risk analysis, as is warranted [15].
Although we adjusted for waitlist year in our multivariate competing risk analyses for
mortality, we assessed an ample study period involving patients who were relisted between
1984–2012. Thus, they were likely managed with different clinical strategies during different
transplant era, which could partly limit the generalizability of our findings. Indeed, when
we performed a subanalysis of our study excluding those patients who were relisted between
1984–1988 and were under azathioprine-based immunosuppression, the adjusted compet-
ing risk regression model revealed a trend to statistical significance for mortality (SHR 1.42;
95% CI, 0.94–2.1; P = 0.09) in relisted patients after graft failure. This could reinforce the
potential negative impact of a previous transplant on mortality, even in patients under CNI-
based immunosuppression where a lower rejection rate was present, which provides more
homogeneity to our study. At the same time, it could also suggest an improvement in the
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predialysis care of transplant patients with severe renal dysfunction in the more recent era.
Accordingly, this could well explain why other authors have not observed a different mor-
tality rate between relisted patients following graft failure compared with transplant-na¨ive
patients in more recent periods (2007–2009), as previously suggested [29]. Nevertheless,
overall mortality in our relisted patients after graft failure was similar (16%) to the mortality
rate observed in relisted patients (around 12%) during 2007–2009, as reported by Mourad
et al in their contemporary cohort of patients [29].
In agreement with Rao et al [5], our patients waitlisted after graft failure had a 1.5-fold
increased risk for all-cause mortality. Because these patients presented significant clinical dif-
ferences compared with TN patients waitlisted for KT, we conducted propensity score analyses
to limit the effect of selection bias by drawing similarly selected individuals from a large pool
of TN patients waitlisted for KT. Indeed, two different marginal structural models, a propen-
sity score-matched analysis and IPTW, were used. Matching has been shown to be the most
effective way to use propensity scores for confounder adjustments. As expected, our matching
strategy resulted in a virtually identical distribution of observed covariates. To reduce con-
founding that can occur with many to-one matching, we performed the analysis with 1:5
matching. We also matched patients closely by listing periods to eliminate immortal time bias
[30]. We found a 1.6–fold increased risk of death among patients waitlisted after graft failure
compared with matched TN waitlisted patients. As a sensitivity analysis, when the primary
endpoint was modeled by IPTW using a competing risk approach, the risk of death for patients
waitlisted after graft failure was almost identical. Nevertheless, despite the use of proper pro-
pensity score analyses for mitigating inclusion bias, we cannot completely exclude residual
confounding when evaluating survival in observational studies.
We used a competing risk analysis, which may be more appropriate when assessing survival
in waitlisted patients, especially in the presence of multiple competing events, as would be
expected in KT candidates [15].
Although relisting after graft failure depends on different criteria worldwide, these patients
have been reported to comprise a high-risk population group [7]. The majority of deaths in
our relisted patients were due to cardiovascular disease, followed by infectious causes. This is
consistent with reports suggesting that several risk factors, irrespective of traditional risk fac-
tors, could contribute to the persisting greater risk of death from cardiovascular and infectious
causes [5,7,8,10]. Indeed, KT recipients are exposed to both uremia-related risk factors, such
as elevated serum creatinine or proteinuria [31,32], and non-traditional risk factors inherent
to transplantation, such as long-term immunosuppression [33]. Indeed, immunosuppression
is a known risk factor for infection and malignancy and transplant failure patients are at very
high risk for septicemia, mainly during the first 6 months after dialysis entry [9,10]. The fact
that the risk for infection-related mortality is higher in relisted patients compared with trans-
plant-na¨ive waitlisted patients supports this argument [4]. In addition, suboptimal treatment
of cardiovascular disorders after KT, related to under-utilization of angiotensin-converting-
enzyme inhibitors and statins due to concerns of worsened allograft function could contribute
to advanced arteriosclerosis and a higher mortality of relisted patients [7,34]. This stage could
thus be a new clinical setting for a higher cardiovascular risk, where the cumulative exposure
to these non-traditional risk factors may underlie the higher mortality in these patients. The
fact that the patients relisted after graft failure were younger and had a lower baseline comor-
bidity burden at dialysis entry supports this view.
The presence of a failed renal allograft may be an ongoing source of low-chronic inflamma-
tion, an established risk factor for mortality in renal patients [35,36]. Additionally, an elevated
risk of death is observed in patients who continue with low doses of immunosuppression after
returning to dialysis in an attempt to preserve residual allograft renal function.
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Interestingly, an increasing waiting-list time between first graft failure and second trans-
plant has been associated with all-cause mortality post-transplantation [37]. A greater total
time on dialysis was observed in our relisted patients compared with transplant-na¨ive wait-
listed patients. Additionally, a higher burden of immunosuppression in our cohort of relisted
patients due to a higher glomerulonephritis rate could be expected. It is plausible, therefore,
that both risk factors could have contributed to a higher mortality in our relisted patients.
This, together with our results, suggests that reducing the waiting time between first graft fail-
ure and second or third KT could improve patient survival not only while on the list, but also
post-transplantation. These results should be taken into account when assessing relisted
patients for a second or third transplant, thereby possibly optimizing survival.
This study has other limitations. First, we did not record important risk factors for survival
in patients undergoing dialysis who return to dialysis therapy after graft failure such as inflam-
matory markers (e.g. PCR levels), serum albumin, residual renal function at dialysis entry and
panel reactive antibodies [1,8,11,38], or some community risk factors, such as obesity or smok-
ing, which have been independently associated with mortality in the general population and
waitlist patients [39]. Unfortunately, no data were available about transplant-related clinical
information, such as immunosuppression, acute rejection or duration of transplant, which
could have impacted on our results concerning mortality on the waiting list. Nor did we record
cases developing new onset diabetes after transplantation, which confers a greater risk of death
in patients on dialysis after graft failure [1,5]. However, we obtained comprehensive informa-
tion about comorbidities included in the CCI and collected complete information on other
clinical conditions and certain community risk factors. We included patients from a single
region in southern Europe, almost exclusively white, which may limit the generalizability of
our results.
Conclusions
Patients on the waiting list for KT after graft failure have an increased risk of death compared
with TN waitlist patients. This information will be useful in daily clinical practice when assess-
ing relisted patients for a retransplant.
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